KIT OF TABLETTED ALIVE RECOMBINANT ORAL BIVACCINE AGAINST SMALLPOX AND HEPATITIS B AND METHOD FOR VACCINATION AT APPLYING THE KIT MENTIONED

FIELD: medicine, immunology. ^ SUBSTANCE: the present innovation deals with specific prophylaxis of smallpox and viral hepatitis B. The kit contains two tablets each contains stabilizing additives, a filler and lyophilized alive viral material worked out based upon recombinant VOV strain at typical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PLJASUNOV IGOR' VLADIMIROVICH, SKARNOVICH MAKSIM OLEGOVICH, SERGEEV ARTEMIJ ALEKSANDROVICH, MISTJURIN JURIJ NIKOLAEVICH, MEL'NIKOV SERGEJ ALEKSEEVICH, NETESOV SERGEJ VIKTOROVICH, EVTIN NIKOLAJ KONSTANTINOVICH, GENERALOV VLADIMIR MIKHAJLOVICH, SANDAKHCHIEV LEV STEPANOVICH, PODKUJKO VALERIJ NIKOLAEVICH, SERGEEV ALEKSANDR NIKOLAEVICH, SHISHKINA LARISA NIKOLAEVNA, PETRISHCHENKO VALENTINA ALEKSEEVNA
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: medicine, immunology. ^ SUBSTANCE: the present innovation deals with specific prophylaxis of smallpox and viral hepatitis B. The kit contains two tablets each contains stabilizing additives, a filler and lyophilized alive viral material worked out based upon recombinant VOV strain at typical VOV properties expressing proteins preS2-S and HBs virus of hepatitis B virus, the first immunizing dosage corresponds to minimal quantity of viral material being sufficient to obtain weak immune response in the body in case of insignificant at insignificant reactogenicity, and immunizing dosage of the second - maximal quantity of viral material that causes pronounced and prolong immune response in the body at no negative side action. The technique of applying the kit of bivaccine tablets, first, one should use the 1st tablet at minimal dosage of bivaccine, as for the 2nd tablet - with maximal dosage of bivaccine it should be taken till the moment of developing humoral answer (in 7-14 d) after injecting the 1st tablet at minimal immunizing dosage of bivaccine. The innovation enables to create stable immunity. ^ EFFECT: higher efficiency. ^ 4 cl, 5 ex, 6 tbl